chevron_leftBack
As of 6 June 2026, ViGenCell Inc. has a market cap of $132.53M USD, ranking #23662 globally and #1055 in South Korea.
It ranks #2128 in the Healthcare sector, and #411 in the Biotechnology industry.
Key Stats
Market Cap
$132.53MUSD
203.15B KRW
Enterprise Value
$106.32MUSD
165.86B KRW
Revenue (TTM)
$181.98KUSD
278.95M KRW
EBITDA (TTM)
-$6.56MUSD
-10.23B KRW
Net Income (TTM)
-$8.19MUSD
-12.56B KRW
PS Ratio
728.3
PB Ratio
3.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Kim Tai Gyu
open_in_new
Employees
64
Founded
2013
Website
vigencell.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -10% | 50% | 85% | 34% | 208% | 262% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
308080
바이젠셀(주)
ISIN: KR7308080001
Shares Out.:
Shares Outstanding:
20.499M1
Shares Float:
16.048M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
9,910 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About ViGenCell Inc.
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 207940
|
$44.48B
33K%
68.19T KRW
|
35.5
|
|
KRX: 068270
|
$27.89B
21K%
42.76T KRW
|
43.8
|
|
KRX: 196170
|
$13.27B
10K%
20.33T KRW
|
146.6
|
|
KRX: 028300
|
$5.46B
4K%
8.37T KRW
|
-
|
|
KRX: 087010
|
$3.96B
3K%
6.07T KRW
|
-
|
|
KRX: 302440
|
$2.23B
2K%
3.42T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
138K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
121K%
|
19.0
|
|
EBR: ARGX
|
$48.08B
36K%
41.39B EUR
|
39.9
|
|
ASX: CSL
|
$43.01B
32K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.72B
32K%
33.71B CHF
|
37.2
|
|
NASDAQ: NTRA
|
$27.6B
21K%
|
-
|
chevron_leftBack